Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0165-1875 +/- Semaglutide in Overweight or Obesity
NCT03707990Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0165-1875 in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2018; status: completed.
02
Drugs
NNC0165-1875
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03707990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707990.